News and Updates

The FDA has lifted a clinical hold on XBiotech's trial for axial spondyloarthritis. Learn how this move impacts the future of rheumatology drug development.

XBiotech has launched a Phase II trial for Vilamakitug, a novel IL-1α inhibitor aimed at treating patients with active axial spondyloarthritis.

A groundbreaking clinical trial has begun testing neural stem cell therapy as a potential treatment to repair brain damage in Huntington’s disease patients.

Novo Nordisk reports a major data breach affecting clinical trial files. Learn about the security risks and the impact on patient data protection.

Explore new Phase III results for tafasitamab in treating DLBCL. Learn how this combination therapy aims to improve progression-free survival in patients.

New Phase III trial data shows promise for Jaypirca in combination therapy for patients with relapsed/refractory Chronic Lymphocytic Leukemia (CLL).

The FDA has approved the belzutifan-pembrolizumab combination to treat high-risk renal cell carcinoma. Learn how this dual therapy aims to prevent recurrence.

Traws Pharma shares dip after the MHRA delays a key influenza clinical trial, demanding additional data. Learn about the impact on the drug pipeline.

IDEAYA Biosciences has launched a Phase 1/2 trial for IDE892, a targeted PRMT5 inhibitor for MTAP-deleted lung and pancreatic cancers. Learn the latest.

Traws Pharma stock drops after the UK regulator delays a planned flu trial. Discover the impact of the MHRA's decision on the company's clinical pipeline.